Based on our patent-pending and proprietary microfluidic technology solution to create stable substance gradients, Gradientech is developing an in vitro diagnostic solution for rapid antibiotic susceptibility testing of positive blood culture samples. By real-time monitoring of bacterial growth and quantification of micro-colonies within precise antibiotic gradients, phenotypic susceptibility guidance is maintained within only 2 hours. This is at least 22 hours faster compared to traditional culture-based methods used for AST in clinics today.
Same day results for all sepsis patients
The introduction of MALDI mass spectrometry within clinical diagnostics has in short time become the golden standard for rapid and cost-effective bacterial identification. Our QuickMIC™ solution for rapid AST can be applied in parallel with, or following bacterial identification. This optimized laboratory workflow enables any clinical laboratory to give susceptibility based antibiotic guidance within the same day as positive blood culture is detected – for all sepsis patients.
Benefits of the QuickMIC™ solution
RAPID AST RESULTS
Generates MIC-values and SIR interpretation in only 2 hours for gram-negative bacteria
PHENOTYPIC FUNCTIONAL RESISTANCE
Susceptibility results are based on viable bacterial growth monitoring and guide to appropriate antibiotic treatment, which is not possible with gene based resistance testing
DETECTS ANY RESISTANCE
Universal solution that detects any functional resistance, not based on specific probes or image database comparison
A Novel Microfluidic Assay for Rapid Phenotypic Antibiotic Susceptibility Testing of Bacteria Detected in Clinical Blood Cultures. December 14, 2016, PLoS ONE
Improved detection algorithms for label-free time-lapse cytometry of bacterial microcolonies for rapid AST. April 11, 2016. ECCMID 2016, Amsterdam, The Netherlands – EPOSTER